Mankind Pharma Ltd (543904) – aksjekurser og nyheter

Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia

Om Mankind Pharma Ltd

Administrerende direktørRajeev Juneja | Sheetal Arora

Ansatte20,5k

Grunnlagt1991

Hovedkontor-

Sektor-

Nettstedmankindpharma.com

Alle verdier i INR	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	36,97 mrd.	35,67 mrd.	34,43 mrd.	40,31 mrd.
Varekostnad	10,62 mrd.	9,78 mrd.	11,71 mrd.	10,98 mrd.
Direkte driftskostnader	10,62 mrd.	9,78 mrd.	11,71 mrd.	10,98 mrd.
Utgifter til forskning og utvikling	-	-	-	-
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	8,25 mrd.	8,24 mrd.	15,80 mrd.	9,14 mrd.
Driftskostnader	19,35 mrd.	18,92 mrd.	14,77 mrd.	21,02 mrd.
Totale driftskostnader	29,98 mrd.	28,70 mrd.	26,48 mrd.	32,00 mrd.
Driftsinntekter	7,00 mrd.	6,97 mrd.	7,95 mrd.	8,30 mrd.
Andre ikke-operasjonelle inntekter	918,70 mill.	727,50 mill.	−2,31 mrd.	450,00 mill.
EBT inkludert uvanlige elementer	6,24 mrd.	5,09 mrd.	6,59 mrd.	7,69 mrd.
EBT uten uvanlige elementer	6,24 mrd.	6,16 mrd.	5,59 mrd.	7,69 mrd.
Kostnad for inntektsskatt	1,04 mrd.	951,20 mill.	997,50 mill.	1,95 mrd.
Faktisk avgiftssats	16,64 %	18,69 %	15,13 %	25,39 %
Andre driftskostnader	8,88 mrd.	8,46 mrd.	−3,26 mrd.	9,63 mrd.
Nettoinntekt	5,12 mrd.	4,09 mrd.	5,54 mrd.	5,68 mrd.
Netto fortjenestemargin	13,84 %	11,46 %	16,10 %	14,09 %
Resultat per aksje	12,38	11,99	13,89	13,74
Rente- og investeringsinntekter	-	-	580,50 mill.	-
Rentekostnader	−1,70 mrd.	−1,57 mrd.	−1,36 mrd.	−1,10 mrd.
Netto rentekostnader	−1,70 mrd.	−1,57 mrd.	−778,20 mill.	−1,10 mrd.
Avskrivnings- og amortiseringskostnader	2,22 mrd.	2,23 mrd.	2,23 mrd.	2,26 mrd.
EBITDA	9,20 mrd.	8,42 mrd.	9,97 mrd.	10,33 mrd.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

Finance

Spør om hva som helst